ACE, angiotensin I converting enzyme, 1636

N. diseases: 1082; N. variants: 82
Disease: Acute Chest Syndrome ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE ACE polymorphism (rs 4343) GG and GA genotypes are more related to STEMI (OR = 1.7, 1.5 respectively) and NSTEMI (OR = 3, 3.8 respectively), and they were more prone to have Percutaneous Coronary Intervention after ACS attack (OR = 11.6, 14.1 respectively). 31195108 2020
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE For patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), it is unclear whether angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are associated with reduced mortality, particularly with preserved left ventricular ejection fraction (LVEF). 31105064 2020
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE This study was conducted to examine the use of optimal medical therapy (OMT), consisting of an antiplatelet, a β-blocker, an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), and a statin combined, after hospital discharge and its relationship with direct medical costs in patients with acute coronary syndromes (ACS) in Tianjin, China. 30770126 2019
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE Guidelines previously recommended use of dual antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) and beta blockers (five classes of drugs) in patients without contraindications or intolerance after acute coronary syndrome (ACS). 31255479 2019
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE Rates of secondary prevention medications were lower among CHD versus ACS (all p < 0.0001): antiplatelet 94.3% vs 98.0%, beta-blocker 72.0% vs 80.0%, lipid-lowering therapy 94.7 vs 97.5%, and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers 69.4% vs 73.7%, respectively. 29934227 2018
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE The secondary prevention treatment for acute coronary syndrome (ACS) is based on the combined use of drugs from four therapeutic classes (beta-blockers, antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). 28124399 2017
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE The D/D genotype of the rs4340 polymorphism is associated with higher ACE concentration levels; however, the polymorphism was not associated with ACS. 28973758 2017
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE The eNOS G894T and ACE I/D polymorphisms are associated with an increased risk of developing ACS after adjusting for classical risk factors for atherosclerosis in the Bulgarian cohort. 26670794 2016
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE In addition, the ACE DD genotype is also associated with greater ACS severity and a higher risk of sudden cardiac death. 22333273 2012
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Thus, the ACE-DD genotype may be associated with ACS in postmenopausal women, particularly in HRT users. 16274774 2005
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE The ACE-ID group (n=335, 116F/219M, mean age 43.6+/-7 years) had 16 hypertensive subjects (4.7%) and 3 subjects with ACS. 15012913 2004